Getting the 411 on TAVR Trials

Slides:

Advertisements

Similar presentations

PARTNER Objective To compare surgical aortic valve replacement (AVR) with transcatheter aortic valve replacement (TAVR) in high-risk patients with severe.

Advertisements

Trancatheter Aortic Valve Implantation (TAVI)

TCT 2015 | San Francisco | October 15, 2015 Transcatheter Aortic Valve Replacement for Failed Surgical Bioprostheses Danny Dvir, MD John G. Webb, MD and.

Tri-leaflet Aortic Valve. Aortic Stenosis Nishimura, RA et al AHA/ACC Valvular Heart Disease Guideline.

Techniques in Transapical AVR Vinod H. Thourani, MD Professor of Surgery and Medicine Chief of Cardiothoracic Surgery, Emory Hospital Midtown Co-Director:

Case #1 Illustration Aortic Root Relationship

EXPANDING INDICATIONS OF TRANSCATHETER HEART VALVE INTERVENTIONS. JACC CARDIOVASCULAR INTERVENTION. DR.RAJAT GANDHI.

© free-ppt-templates.com 2017 AHA/ACC Focused Update of Valvular Heart Disease Guideline of 2014 DR. OMAR SHAHID TR CARDIOLOGY SZH.

Patients the Surgeon Should Refer for TAVR

Extending the Boundaries of TAVR: Future Directions

Overview of the 2012 Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee meeting on the Edwards SAPIEN.

TAVR Medtronic CoreValve® Subclavian Approach Clinical Data

Expanding Indications for TAVR – What Should Be Next?

Are we ready to perform TAVI in Intermediate Risk Patients?

Structural Heart Live Cases

Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis Description: The goal of the trial was to assess.

Algorithm for the management of aortic valve stenosis

Addressing the Challenges in Primary and Secondary Stroke Prevention

Opportunities to Study Valve Iterations and Modifications in the US

Insights from the NCDR® STS/ACC TVT Registry.

CoreValve Continued Access Study Shows Continued Improvement in 1-Year Outcomes With Self-Expanding Transcatheter Aortic Valve Replacement Steven J. Yakubov,

Pathophysiology of valvular heart diseases

A: Edwards Sapien percutaneous aortic valve (Reproduced with permission from Edwards Lifesciences, Irvine, California.) B: Medtronic CoreValve, currently.

Is It Feasible to Complete RCT for Intermediate Risk Studies in Europe and the US Lessons Form SURTAVI? Patrick W. Serruys Professor of Cardiology, International.

Diabetic Dyslipidemia in Practice

Risk Stratification of Severe, Symptomatic Aortic Stenosis Patients

The Ever-Expanding Patient Pool for TAVR:

NOACs for Cancer-Associated Thrombosis:

Anticoagulants in Interventional Cardiology:

Know Your ABCs: Antiplatelet Therapy, Benefits/Bleeding, and Cardiac Surgery State of the Art: The Role of Antiplatelet Therapy in the Cardiac Surgical.

US Guidelines US Guidelines Low-risk Patients.

Progression After Cancer Immunotherapy in Advanced NSCLC

Nat. Rev. Cardiol. doi: /nrcardio

Optimizing the Treatment of Recurrent/Metastatic SCCHN

Antithrombotics and PAD: A New Paradigm in Practice

Selecting NOACs for High-Risk Patients

Panelists. One Size May Not Fit All: A New Aspirin Option for the High-Risk Patient.

Anticoagulation Therapy in Patients Post-TAVR

PAH Therapy Revisited.

Seizures in the Elderly: Treatment and Special Considerations

More Than Meets the Eye.

PARTNER 2A Trial design: Intermediate-risk patients with aortic stenosis (STS PROM score 4-8%) were randomized to undergo either TAVR or SAVR, stratified.

CoreValve US Pivotal Trial High-Risk Arm Device and Access Routes.

How to Optimize TAVR Outcomes

TAVR and the Risk of Thrombosis

Program Goals Disclaimer Overview Assessing Disease Activity.

Remote Patient Management:

Management of Patients With Aortic Valve Stenosis

Translating the Latest and Greatest Advances in PAH Into Clinical Practice.

Treating to Target in MS

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

Using Heart Rate as a Biomarker in Clinical Practice.

Transatlantic editorial on transcatheter aortic valve replacement

Aspects to be considered by the Heart Team for the decision between TAVR and SAVR in patients at increased surgical risk. Aspects to be considered by the.

Rheumatic fever. Etiology. Diagnosis. Heart Valvular Diseases.

Identifying High-Risk AF Patients

The Road to Quality Improvement in HER2-Positive Breast Cancer

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

Factor Xa Inhibitors in PAD

Typical Patient Presentation

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion.

Program Goal. Program Goal Disclaimer Overview.

Selecting Treatment Approaches in Hemophilia

At the Crossroads of Coagulation

Pulmonary Arterial Hypertension and Hospitalizations

Commentary: When a choice is not an echo

My PAH Patient.

Expert Perspectives.

Patient selection process in the present study.

Presentation transcript:

Getting the 411 on TAVR Trials

Aortic Stenosis

2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease

Suboptimal Treatment of AS

PARTNER 1 Design

PARTNER TRIALS

PARTNER 5-Year Results

PARTNER 1 30-Day and 1-Year Results

TAVR Platforms

SAPIEN XT CoreValve® Lotus™

CHOICE Trial

STS/ACC TVT Registry™

STS/ACC TVT Registry (cont)

STS/ACC TVT Registry (cont)

2014 AHA/ACC Guidelines

2014 AHA/ACC Guidelines (cont)

2014 AHA/ACC Guidelines (cont)

STS Score

SurTAVI Trial

TAVR Future Considerations

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)